Kramarczyk, Daniel published the artcileInhibition of celecoxib crystallization by mesoporous silica – Molecular dynamics studies leading to the discovery of the stabilization origin, Synthetic Route of 169590-42-5, the publication is European Journal of Pharmaceutical Sciences (2022), 106132, database is CAplus and MEDLINE.
In this article, the effect of mesoporous silica (MS) on the phys. stability and mol. dynamics of the amorphous form of Celecoxib (CEL) is investigated. It has been proven that the recrystallization process of CEL slows down with increasing the MS content. Beside the elongation of stabilization time with the increase silica content leads to an increase in the amorphous drug fraction remaining after the finished crystallization The conducted analyses show that the observed inhibition of CEL’s recrystallization is associated with the formation of a monomol. drug layer on the silica’s surface. The performed non-isothermal dielec. studies of CEL + MS systems having both fully and partially amorphous CEL shows that the biggest impact of the drug’s the temperature dependences of structural relaxation time τα(T) has a crystalline fraction of the API. Silica, even in high concentration, does not modify the temperature dependence of structural relaxation of CEL.
European Journal of Pharmaceutical Sciences published new progress about 169590-42-5. 169590-42-5 belongs to amides-buliding-blocks, auxiliary class Sulfamide,Immunology/Inflammation,COX, name is 4-(5-(p-Tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide, and the molecular formula is C17H14F3N3O2S, Synthetic Route of 169590-42-5.
Referemce:
https://en.wikipedia.org/wiki/Amide,
Amide – an overview | ScienceDirect Topics